The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Salix Pharmaceuticals Ltd

Nasdaq: SLXP
Last

(U.S.) $103.25

Today's change+0.91 +0.89%
Updated November 26 4:15 PM EST. Delayed by at least 15 minutes.
 

Salix Pharmaceuticals Ltd

Nasdaq: SLXP
Last

(U.S.) $103.25

Today's change+0.91 +0.89%
Updated November 26 4:15 PM EST. Delayed by at least 15 minutes.

Salix Pharmaceuticals Ltd up (U.S.)$0.91

Salix Pharmaceuticals Ltd closed up Wednesday by (U.S.)$0.91 or 0.89% to (U.S.)$103.25. Shares have lost 0.37% over the last five days, but have gained 14.80% over the last year to date. This security has outperformed the S&P 500 by 6.86% during the last year.

Key company metrics

  • Open(U.S.) $102.29
  • Previous close(U.S.) $102.34
  • High(U.S.) $103.45
  • Low(U.S.) $101.47
  • Bid / Ask-- / --
  • YTD % change+14.80%
  • Volume962,089
  • Average volume (10-day)2,943,500
  • Average volume (1-month)3,677,520
  • Average volume (3-month)2,652,076
  • 52-week range(U.S.) $82.52 to (U.S.) $172.98
  • Beta0.88
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward19.13×
  • Forward PEG1.46×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.27
Updated November 26 4:15 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-5.58%

Salix Pharmaceuticals Ltd has a net profit margin of -5.58%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.23%Sector:HealthcareIndustry:Pharmaceuticals - Generic & Specialty
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2014Q2/2014Q1/2014Q4/2013
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Revenue355382384258
Total other revenue--------
Total revenue355382384258
Gross profit268278269201
Total cost of revenue8610411657
Total operating expense434334422162
Selling / general / administrative16612519580
Research & development51395336
Depreciation / amortization55555511
Interest expense (income), net operating--------
Unusual expense (income)77104-23
Other operating expenses, total--------
Operating income-8048-3896
Interest income (expense), net non-operating-44-42-42-15
Gain (loss) on sale of assets--------
Other--------
Income before tax-1256-8081
Income after tax-893-4452
Income tax, total-363-3629
Net income-893-4452
Total adjustments to net income--------
Net income before extra. items-893-4452
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-893-4452
Inc. avail. to common incl. extra. items-893-4452
Diluted net income-893-4452
Dilution adjustment000--
Diluted weighted average shares64756368
Diluted EPS excluding extraordinary itemsvalue per share-1.390.04-0.690.77
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.610.12-0.650.55